Zhengye Biotechnology Holding Limited (ZYBT) Fair Value 2026

ZYBT · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.2 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (38/100)

Quick Summary — As of 2026-08-28, Zhengye Biotechnology Holding Limited (ZYBT) trades at $1.73, versus a $0.42 median fair value across its 5 active models — 76.0% below the current price. QOC: 6.2/10. Value Trap Risk: 38/100 (LOW). 5/13 models active. Within that set, the Bayesian DCF component alone returns $0.07.

Key Facts

Ticker
ZYBT
Price
$1.73
Quality Score
6.2/10
Value Trap Risk
38/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Zhengye Biotechnology Holding Limited (ZYBT) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Zhengye Biotechnology Holding Limited (ZYBT) appears overvalued as of : the median of 5 independent fair value estimates is $0.42, 76.0% below the current price of $1.73. Estimates range from $0.07 to $0.85. ZYBT scores 6.2/10 on fundamental quality and 38/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ZYBT’s -76.0% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Zhengye Biotechnology Holding Limited Stock in 2026? →

What Fair Value Does Each Model Give ZYBT?

5 Intrinsic Value Models vs. Current Price ($1.73)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.07 -95.7%
Ensemble · Low Conviction
 $0.42 -76.0%
Unlock the Full Matrix

Access 3 additional models including ML-RIV, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is ZYBT's Fair Value Range?

Spread across 5 independent models · $0.07 to $0.85

CirclFi's 5 active models place Zhengye Biotechnology Holding Limited (ZYBT) between $0.07 and $0.85 per share, a spread of 186% of the median. The median of that range — $0.42 — is the fair value CirclFi publishes for ZYBT, against a current price of $1.73.

Low · Bayesian DCFHigh · RCMH-DCF
$0.07median $0.42$0.85
Where the range comes from
Most bearish modelBayesian DCF$0.07
Most bullish modelRCMH-DCF$0.85
Model agreement0 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ZYBT. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ZYBT, not a CirclFi price target. How each model works →

What Is Zhengye Biotechnology Holding Limited (ZYBT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Zhengye Biotechnology Holding Limited's intrinsic value is estimated at $0.42, suggesting the stock is overvalued at its current price of $1.73. With 5 out of 5 models flagging downside (-76.0% vs price), the market may be pricing in unsustainable growth. Model dispersion is worth noting: RCMH-DCF targets $0.85 (-51.1%), versus Bayesian DCF at $0.07 (-95.7%). This +44.6% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ZYBT?

5 of 13 models are currently active for ZYBT. All 5 active models suggest the stock trades above fair value. Taken together, their median fair value for ZYBT is $0.42 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.07 on its own, implying -95.7% downside from the current price. See which stocks rank higher →

How Does ZYBT Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, ZYBT ranks #45 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Within the Drug Manufacturers - Specialty & Generic space, Zhengye Biotechnology Holding Limited competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ZYBT a Value Trap?

CirclFi's Value Trap algorithm assigns ZYBT a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Zhengye Biotechnology Holding Limited. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Zhengye Biotechnology Holding Limited is rated at 6.2/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +44.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ZYBT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ZYBT's 5 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Zhengye Biotechnology Holding Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

CPIXCumberland Pharmaceuticals Inc.QOC 6.3TXMDTherapeuticsMD, Inc.QOC 6.2CRDLCardiol Therapeutics Inc.QOC 6.3DERMJourney Medical CorporationQOC 6.2ALVOAlvotechQOC 6.3EVOEvotec SEQOC 6.2INMInMed Pharmaceuticals Inc.QOC 5.2KAYSKaya Holdings, Inc.QOC 3.9AMRXAmneal Pharmaceuticals, Inc.QOC 8.3UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: CPIX · TXMD · CRDL · DERM · ALVO · EVO · INM · KAYS · AMRX · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to ZYBT?

7 companies across all industries closest to ZYBT’s Quality of Company score of 6.2/10.

FSEAFirst Seacoast Bancorp, Inc.QOC 6.2WVVIWillamette Valley Vineyards, Inc.QOC 6.2BFRGBullfrog AI Holdings, Inc.QOC 6.2RHEPRegional Health Properties, Inc.QOC 6.2EVMNEvommune, Inc.QOC 6.2CDXSCodexis, Inc.QOC 6.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FSEA · WVVI · BFRG · RHEP · EVMN · CDXS · NVDA

Where Does ZYBT Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

ZYBT is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Zhengye Biotechnology Holding Limited’s Valuation?

What is Zhengye Biotechnology Holding Limited's intrinsic value in 2026?

CirclFi puts Zhengye Biotechnology Holding Limited (ZYBT)'s intrinsic value at $0.42 — the median of 5 independent model estimates as of 2026-08-28, ranging from $0.07 to $0.85. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.07 on its own. The Quality of Company score is 6.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ZYBT overvalued or undervalued right now?

At $1.73, 0 of 5 active models suggest ZYBT may be undervalued, while 5 indicate potential overvaluation. The median of all 5 fair value estimates is $0.42, 76.0% below the current price of $1.73 — a consensus view that ZYBT is overvalued. The assessment depends on which methodology best fits Zhengye Biotechnology Holding Limited's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.2 mean for ZYBT?

Zhengye Biotechnology Holding Limited's QOC of 6.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ZYBT?

CirclFi analyzes ZYBT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ZYBT?

Of the 5 models currently active on ZYBT, RCMH-DCF is the most bullish at $0.85 per share, and Bayesian DCF is the most bearish at $0.07. CirclFi's published fair value for ZYBT is the median of that range, $0.42, not either extreme. The gap between the two ends equals 186% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ZYBT a value trap in 2026?

Zhengye Biotechnology Holding Limited's Value Trap score is 38/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Zhengye Biotechnology Holding Limited (ZYBT) has a median fair value of $0.42 — 76.0% below the current price of $1.73 — as of 2026-08-28.” Source: circlfi.com/stock/ZYBT/ · Methodology
Primary sources for this ZYBT valuation

Market data for ZYBT as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on ZYBT.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for ZYBT Unlock All 5 — $39/mo